Luminate meets primary endpoint in phase 2 trial for dry AMD

A treatment candidate for dry age-related macular degeneration met its primary endpoint in a phase 2 study, with 48% of patients gaining at least eight letters of vision, according to a press release from Allegro Ophthalmics.
The prospective, randomized, double-masked, placebo-controlled trial evaluated safety and efficacy of Luminate (risuteganib) in intermediate dry AMD. Patients in the treatment arm were randomly assigned to receive one 1-mg Luminate (risuteganib) intravitreal injection at baseline and a second at week 16, while those in the sham arm received a sham injection at baseline

Full Story →